A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion
Intratumoral regulatory T cells (Tregs) express high levels of CD25 and TIGIT, which are also recognized as markers of effector T cell (Teff) activation. Targeting these molecules each alone with monoclonal antibodies (mAbs) poses a risk of concurrently depleting both Teffs and peripheral Tregs, the...
Saved in:
| Published in | Molecular therapy |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
07.09.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Intratumoral regulatory T cells (Tregs) express high levels of CD25 and TIGIT, which are also recognized as markers of effector T cell (Teff) activation. Targeting these molecules each alone with monoclonal antibodies (mAbs) poses a risk of concurrently depleting both Teffs and peripheral Tregs, thereby compromising the effectiveness and selectivity of intratumoral Treg depletion. Here, leveraging the increased abundance of CD25+ TIGIT+ double-positive Tregs in the solid tumor microenvironment (but not in peripheral tissues), we explore the feasibility of using a CD25×TIGIT bispecific antibody (bsAb) to selectively deplete intratumoral Tregs. We initially constructed a bsAb co-targeting mouse CD25 and TIGIT, NSWm7210, and found that NSWm7210 conferred enhanced intratumoral Treg depletion, Teff activation, and tumor suppression as compared to the parental monotherapies in mouse models. We subsequently constructed a bsAb co-targeting human CD25 and TIGIT (NSWh7216), which preferentially eliminated CD25+ TIGIT+ double-positive cells over single-positive cells in vitro. NSWh7216 exhibited enhanced anti-tumor activity without toxicity of peripheral Tregs in CD25 humanized mice compared to the parental monotherapies. Our study illustrates the use of CD25×TIGIT bsAbs as effective agents against solid tumors based on selective depletion of intratumoral Tregs.
[Display omitted]
Sui and colleagues developed bispecific antibodies (bsAbs) targeting CD25 and TIGIT by leveraging the abundance of immune-suppressive CD25+ TIGIT+ double-positive regulatory T cells (Tregs) in tumor microenvironment. Experiments with mouse models showed that the bsAbs safely enhances intratumoral Tregs depletion and tumor suppression and outperforms the parental monoclonal antibodies. |
|---|---|
| AbstractList | Intratumoral regulatory T cells (Tregs) express high levels of CD25 and TIGIT, which are also recognized as markers of effector T cell (Teff) activation. Targeting these molecules each alone with monoclonal antibodies (mAbs) poses a risk of concurrently depleting both Teffs and peripheral Tregs, thereby compromising the effectiveness and selectivity of intratumoral Treg depletion. Here, leveraging the increased abundance of CD25+ TIGIT+ double-positive Tregs in the solid tumor microenvironment (but not in peripheral tissues), we explore the feasibility of using a CD25×TIGIT bispecific antibody (bsAb) to selectively deplete intratumoral Tregs. We initially constructed a bsAb co-targeting mouse CD25 and TIGIT, NSWm7210, and found that NSWm7210 conferred enhanced intratumoral Treg depletion, Teff activation, and tumor suppression as compared to the parental monotherapies in mouse models. We subsequently constructed a bsAb co-targeting human CD25 and TIGIT (NSWh7216), which preferentially eliminated CD25+ TIGIT+ double-positive cells over single-positive cells in vitro. NSWh7216 exhibited enhanced anti-tumor activity without toxicity of peripheral Tregs in CD25 humanized mice compared to the parental monotherapies. Our study illustrates the use of CD25×TIGIT bsAbs as effective agents against solid tumors based on selective depletion of intratumoral Tregs.Intratumoral regulatory T cells (Tregs) express high levels of CD25 and TIGIT, which are also recognized as markers of effector T cell (Teff) activation. Targeting these molecules each alone with monoclonal antibodies (mAbs) poses a risk of concurrently depleting both Teffs and peripheral Tregs, thereby compromising the effectiveness and selectivity of intratumoral Treg depletion. Here, leveraging the increased abundance of CD25+ TIGIT+ double-positive Tregs in the solid tumor microenvironment (but not in peripheral tissues), we explore the feasibility of using a CD25×TIGIT bispecific antibody (bsAb) to selectively deplete intratumoral Tregs. We initially constructed a bsAb co-targeting mouse CD25 and TIGIT, NSWm7210, and found that NSWm7210 conferred enhanced intratumoral Treg depletion, Teff activation, and tumor suppression as compared to the parental monotherapies in mouse models. We subsequently constructed a bsAb co-targeting human CD25 and TIGIT (NSWh7216), which preferentially eliminated CD25+ TIGIT+ double-positive cells over single-positive cells in vitro. NSWh7216 exhibited enhanced anti-tumor activity without toxicity of peripheral Tregs in CD25 humanized mice compared to the parental monotherapies. Our study illustrates the use of CD25×TIGIT bsAbs as effective agents against solid tumors based on selective depletion of intratumoral Tregs. Intratumoral regulatory T cells (Tregs) express high levels of CD25 and TIGIT, which are also recognized as markers of effector T cell (Teff) activation. Targeting these molecules each alone with monoclonal antibodies (mAbs) poses a risk of concurrently depleting both Teffs and peripheral Tregs, thereby compromising the effectiveness and selectivity of intratumoral Treg depletion. Here, leveraging the increased abundance of CD25 TIGIT double-positive Tregs in the solid tumor microenvironment (but not in peripheral tissues), we explore the feasibility of using a CD25×TIGIT bispecific antibody (bsAb) to selectively deplete intratumoral Tregs. We initially constructed a bsAb co-targeting mouse CD25 and TIGIT, NSWm7210, and found that NSWm7210 conferred enhanced intratumoral Treg depletion, Teff activation, and tumor suppression as compared to the parental monotherapies in mouse models. We subsequently constructed a bsAb co-targeting human CD25 and TIGIT (NSWh7216), which preferentially eliminated CD25 TIGIT double-positive cells over single-positive cells in vitro. NSWh7216 exhibited enhanced anti-tumor activity without toxicity of peripheral Tregs in CD25 humanized mice compared to the parental monotherapies. Our study illustrates the use of CD25×TIGIT bsAbs as effective agents against solid tumors based on selective depletion of intratumoral Tregs. Intratumoral regulatory T cells (Tregs) express high levels of CD25 and TIGIT, which are also recognized as markers of effector T cell (Teff) activation. Targeting these molecules each alone with monoclonal antibodies (mAbs) poses a risk of concurrently depleting both Teffs and peripheral Tregs, thereby compromising the effectiveness and selectivity of intratumoral Treg depletion. Here, leveraging the increased abundance of CD25+ TIGIT+ double-positive Tregs in the solid tumor microenvironment (but not in peripheral tissues), we explore the feasibility of using a CD25×TIGIT bispecific antibody (bsAb) to selectively deplete intratumoral Tregs. We initially constructed a bsAb co-targeting mouse CD25 and TIGIT, NSWm7210, and found that NSWm7210 conferred enhanced intratumoral Treg depletion, Teff activation, and tumor suppression as compared to the parental monotherapies in mouse models. We subsequently constructed a bsAb co-targeting human CD25 and TIGIT (NSWh7216), which preferentially eliminated CD25+ TIGIT+ double-positive cells over single-positive cells in vitro. NSWh7216 exhibited enhanced anti-tumor activity without toxicity of peripheral Tregs in CD25 humanized mice compared to the parental monotherapies. Our study illustrates the use of CD25×TIGIT bsAbs as effective agents against solid tumors based on selective depletion of intratumoral Tregs. [Display omitted] Sui and colleagues developed bispecific antibodies (bsAbs) targeting CD25 and TIGIT by leveraging the abundance of immune-suppressive CD25+ TIGIT+ double-positive regulatory T cells (Tregs) in tumor microenvironment. Experiments with mouse models showed that the bsAbs safely enhances intratumoral Tregs depletion and tumor suppression and outperforms the parental monoclonal antibodies. |
| Author | Zhang, Huixiang Tian, Xinxin Si, Guangxu Sui, Jianhua Du, Kaixin Wei, Xin Wei, Zhizhong Yang, Yajing Zhao, Linlin Wang, Kailun He, Miaomiao Yang, Fang Fan, Ruihua Li, Yulu |
| Author_xml | – sequence: 1 givenname: Xin surname: Wei fullname: Wei, Xin organization: School of Life Sciences, Beijing Normal University, Beijing 100875, China – sequence: 2 givenname: Linlin surname: Zhao fullname: Zhao, Linlin organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 3 givenname: Fang surname: Yang fullname: Yang, Fang organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 4 givenname: Yajing surname: Yang fullname: Yang, Yajing organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 5 givenname: Huixiang surname: Zhang fullname: Zhang, Huixiang organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 6 givenname: Kaixin surname: Du fullname: Du, Kaixin organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 7 givenname: Xinxin surname: Tian fullname: Tian, Xinxin organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 8 givenname: Ruihua surname: Fan fullname: Fan, Ruihua organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 9 givenname: Guangxu surname: Si fullname: Si, Guangxu organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 10 givenname: Kailun surname: Wang fullname: Wang, Kailun organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 11 givenname: Yulu surname: Li fullname: Li, Yulu organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 12 givenname: Zhizhong surname: Wei fullname: Wei, Zhizhong organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 13 givenname: Miaomiao surname: He fullname: He, Miaomiao organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China – sequence: 14 givenname: Jianhua orcidid: 0000-0002-1272-9662 surname: Sui fullname: Sui, Jianhua email: suijianhua@nibs.ac.cn organization: National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39245938$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kMlO5DAQhi3EiG3mCUZCPs4lwXZWH-aAmq0lJC49Z8tLhXYriYPtIPWT8EC8GO5uhiOnKv36qsr-ztHx6EZA6DclOSW0vtrk2yGuIWeElTnhOaHkCJ3RilUZSdHxV0_rU3QewiZ1tOL1CTotOCsrXrRnaLrGixtWvb-tlvfLFVY2TKBtZzWWY7TKmS22o5k1hH2QxXlwHksd7auNWxzX3s3Paxygh10GiY5e7inZ45WHZ6yh77GBqYdo3fgT_ehkH-DXZ71A_-5uV4uH7PHpfrm4fsw0rco2a5qybWtScChZzaVpFXDVgZSgupqohkmpOkU73UrOCG9a0rTaNMA0MaToWHGB_hz2Tt69zBCiGGzYPUWO4OYgCkoYqXlT8oQWB1R7F4KHTkzeDtJvBSVip1psxF612KkWhIukOk1dfh6Y1QDma-a_2wT8PQCQvvlqwYugLYwajPVJljDOfnvgA_gSlMo |
| Cites_doi | 10.3322/caac.21834 10.1038/s43018-020-00133-0 10.1002/eji.200939613 10.4049/jimmunol.0803053 10.1158/2159-8290.CD-20-1445 10.1016/j.molimm.2004.07.030 10.1016/j.immuni.2016.05.001 10.1080/19420862.2015.1136762 10.1016/j.ymthe.2021.01.006 10.4049/jimmunol.155.3.1151 10.1158/1078-0432.CCR-18-0762 10.1080/19420862.2018.1466767 10.1080/19420862.2023.2180794 10.1002/eji.201847659 10.1158/1535-7163.MCT-20-0464 10.4049/jimmunol.163.10.5211 10.1002/ijc.24556 10.1002/cpim.95 10.1186/s40425-018-0316-z 10.1038/nrc2250 10.4049/jimmunol.1003081 10.1038/nri3156 10.1186/s12967-022-03480-x 10.1074/jbc.M116.767749 10.4049/jimmunol.1901413 10.1126/sciimmunol.add8005 10.1126/sciimmunol.abn6173 10.1002/bit.20151 10.1126/science.1160062 10.1038/ni1428 10.1053/j.gastro.2007.03.102 10.1172/jci.insight.121157 10.1073/pnas.1812186116 10.1111/imr.12518 10.1016/j.it.2014.05.002 10.7554/eLife.26738 10.1158/1535-7163.MCT-11-0820 10.1002/eji.1830170706 10.1016/j.jcmgh.2021.03.003 10.1084/jem.20130579 10.1200/JCO.2021.39.15_suppl.2583 10.1016/j.apsb.2023.05.023 10.1016/j.immuni.2014.02.012 10.1016/j.it.2022.08.001 10.1038/srep40098 10.1158/1538-7445.AM2020-2288 10.1172/JCI81187 10.1016/j.immuni.2017.03.013 10.1016/j.ymeth.2013.07.017 10.4049/jimmunol.1402381 10.1007/s13311-017-0553-8 10.1186/s12916-015-0455-8 10.1002/eji.201041136 10.1016/j.annonc.2020.08.1714 10.1126/science.abe6474 10.1158/1538-7445.AM2023-CT110 10.1186/s13045-020-00876-4 10.1146/annurev-immunol-042718-041717 10.1080/19420862.2015.1062192 10.1093/protein/9.7.617 10.1158/1538-7445.AM2023-5674 10.1146/annurev-cancerbio-030419-033428 10.1016/j.lungcan.2012.04.011 10.1038/ni1536 10.1080/19420862.2015.1022695 10.4049/jimmunol.158.2.649 10.3389/fimmu.2015.00368 10.1016/j.esmoop.2023.101184 10.1038/s41598-021-02449-y 10.1073/pnas.0903474106 |
| ContentType | Journal Article |
| Copyright | 2024 The Author(s) Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2024 The Author(s) – notice: Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. |
| DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.ymthe.2024.09.010 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1525-0024 |
| ExternalDocumentID | 10_1016_j_ymthe_2024_09_010 39245938 S1525001624005975 |
| Genre | Journal Article |
| GroupedDBID | --- --K 0R~ 0SF 123 1B1 29M 2WC 36B 39C 3V. 4.4 53G 6I. 7X7 88E 8FE 8FH 8FI 8FJ AACTN AAEDW AAFTH AALRI AAMRU AAVLU AAXUO ABAWZ ABJNI ABMAC ABUDA ABUWG ABVKL ACGFO ACGFS ACPRK ADBBV ADFRT ADMUD ADVLN AENEX AFKRA AFTJW AGAYW AHMBA AITUG AKAPO AKRWK ALIPV ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS ASPBG AVWKF AZFZN BAWUL BBNVY BENPR BHPHI BPHCQ BVXVI CAG CCPQU COF CS3 DIK DU5 E3Z EBS EJD EMB EMOBN F5P FDB FEDTE FRP FYUFA GX1 HCIFZ HVGLF HYE HZ~ IHE JIG JSO KQ8 LG5 LK8 M1P M41 M7P NCXOZ NQ- O9- OK1 P2P PQQKQ PROAC PSQYO RCE RIG RNS RNTTT ROL RPM RPZ SEW SSZ SV3 TR2 UHS W2D XPP ZMT NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c1548-774886039e4269ad8be9bfeaaebf60b72aabfb1fc8a920978078cd7e2c0d03f23 |
| ISSN | 1525-0016 1525-0024 |
| IngestDate | Sat Oct 26 03:54:49 EDT 2024 Wed Sep 25 14:04:11 EDT 2024 Sat Nov 02 12:31:56 EDT 2024 Sat Sep 21 15:55:26 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Treg depletion bispecific antibody intratumoral regulatory T cells CD25 bsAb TIGIT |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c1548-774886039e4269ad8be9bfeaaebf60b72aabfb1fc8a920978078cd7e2c0d03f23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-1272-9662 |
| OpenAccessLink | https://dx.doi.org/10.1016/j.ymthe.2024.09.010 |
| PMID | 39245938 |
| PQID | 3102069749 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3102069749 crossref_primary_10_1016_j_ymthe_2024_09_010 pubmed_primary_39245938 elsevier_sciencedirect_doi_10_1016_j_ymthe_2024_09_010 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-Sep-07 |
| PublicationDateYYYYMMDD | 2024-09-07 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-Sep-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular therapy |
| PublicationTitleAlternate | Mol Ther |
| PublicationYear | 2024 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Kurtulus, Sakuishi, Ngiow, Joller, Tan, Teng, Smyth, Kuchroo, Anderson (bib35) 2015; 125 Simpson, Li, Montalvo-Ortiz, Sepulveda, Bergerhoff, Arce, Roddie, Henry, Yagita, Wolchok (bib77) 2013; 210 Zhou, Ding, Pan, Zhu, Li, Zheng (bib3) 2009; 125 Rogers, Weaver, Kraus, Li, Li, Bucy (bib20) 1997; 158 Finn, Ryoo, Hsu, Li, Burgoyne, Cotter, Badhrinarayanan, Wang, Yin, Rao Edubilli (bib40) 2023 Colombo, Piconese (bib73) 2007; 7 Mazor, Sachsenmeier, Yang, Hansen, Filderman, Mulgrew, Wu, Dall'Acqua (bib16) 2017; 7 Stanietsky, Simic, Arapovic, Toporik, Levy, Novik, Levine, Beiman, Dassa, Achdout (bib29) 2009; 106 Weiskopf, Weissman (bib55) 2015 Kapic, Becic, Kusturica (bib23) 2004; 58 Boyman, Sprent (bib47) 2012; 12 Ritter, Marshal, Pulukkunat, Pereira, Rakhmilevich, Gawdzik, Wiwczar, Russell, McCormick, Aversa (bib13) 2022; 10 Yu, Song, Tian (bib78) 2020; 13 Sakaguchi, Mikami, Wing, Tanaka, Ichiyama, Ohkura (bib1) 2020; 38 Joller, Hafler, Brynedal, Kassam, Spoerl, Levin, Sharpe, Kuchroo (bib28) 2011; 186 Pereira, Chan, Lin, Song (bib58) 2018; 10 Han, Cai, Grein, Perera, Wang, Bigler, Ueda, Rosahl, Pinheiro, LaFace (bib36) 2020; 11 Cohen Saban, Yalin, Landsberger, Salomon, Alva, Feferman, Amit, Dahan (bib76) 2023; 8 Solomon, Amann, Goubier, Arce Vargas, Zervas, Qing, Henry, Ghorani, Akarca, Marafioti (bib24) 2020; 1 Levin, Taft, Brandt, Bucher, Howard, Chadwick, Johnston, Hammond, Bontadelli, Ardourel (bib27) 2011; 41 Setiady, Coccia, Park (bib79) 2010; 40 Du, Zhou, Cao, Peng, Yang, Hu, Tan, Ding, Han (bib81) 2023; 11 Zheng, Qin, Si, Wang, Xing, Gao, Ren, Wang, Wu, Zhang (bib41) 2021; 374 Pang, Huang, Zhong, Zhang, Wang, Xia, Li (bib65) 2023; 15 Dovedi, Elder, Yang, Sitnikova, Irving, Hansen, Hair, Jones, Hasani, Wang (bib61) 2021; 11 Huang, Shah, Barat, Lam, Gorlatov, Ciccarone, Tamura, Moore, Diedrich (bib74) 2020; 129 Erfani, Mehrabadi, Ghayumi, Haghshenas, Mojtahedi, Ghaderi, Amani (bib4) 2012; 77 Liu, Wang, Liu, Han, Sun, Zhang, Guo, Zhang (bib52) 2022; 20 Berezhnoy, Sumrow, Stahl, Shah, Liu, Li, Hao, De Costa, Kaul, Bendell (bib62) 2020; 1 Yang, Zhao, Wei, Yang, Liu, Li, Tian, Liu, Lü, Sui (bib37) 2020; 205 Rousseau, Parisi, Barlesi (bib69) 2023; 8 Oosterhoff, Larsen, van der Schoot, Vidarsson (bib57) 2022; 43 Ha, Tanaka, Kibayashi, Tanemura, Sugiyama, Wing, Lim, Teng, Adeegbe, Newell (bib6) 2019; 116 Piccione, Juarez, Liu, Tseng, Ryan, Narayanan, Wang, Weiskopf, Majeti (bib11) 2015; 7 Houacine, Marie-Cardine, Le Roy, Giustiniani, Abes, Chrétien, Fattori, Gorvel, Bensussan, Olive (bib25) 2021; 9 Yamane-Ohnuki, Kinoshita, Inoue-Urakubo, Kusunoki, Iida, Nakano, Wakitani, Niwa, Sakurada, Uchida (bib59) 2004; 87 Sharma, Subudhi, Blando, Scutti, Vence, Wargo, Allison, Ribas, Sharma (bib7) 2019; 25 Sakaguchi, Sakaguchi, Asano, Itoh, Toda (bib50) 1995; 155 Wing, Onishi, Prieto-Martin, Yamaguchi, Miyara, Fehervari, Nomura, Sakaguchi (bib18) 2008; 322 Dougall, Kurtulus, Smyth, Anderson (bib30) 2017; 276 Ge, Zhou, Campos Carrascosa, Gausvik, Boor, Noordam, Doukas, Polak, Terkivatan, Pan (bib53) 2021; 12 Wang, Erbe, Hank, Morris, Sondel (bib54) 2015; 6 Onizuka, Tawara, Shimizu, Sakaguchi, Fujita, Nakayama (bib67) 1999; 59 Ridgway, Presta, Carter (bib45) 1996; 9 Berezhnoy, Shah, Liu, Jill, Fieger, Smith, Chen, Tamura, Bonvini, Diedrich, Moore (bib14) 2020; 80 Schaefer, Regula, Bähner, Schanzer, Croasdale, Dürr, Gassner, Georges, Kettenberger, Imhof-Jung (bib46) 2011; 108 Zheng, Moores, Jarantow, Pardinas, Chiu, Zhou, Wang (bib72) 2016; 8 Frentzas, Meniawy, Kao, Wang, Zuo, Zheng, Tan (bib70) 2021; 39 Couper, Lanthier, Perona-Wright, Kummer, Chen, Smiley, Mohrs, Johnson (bib8) 2009; 182 Fu, Xu, Liu, Shi, Zhao, Fu, Zhang, Yang, Zhang, Zhou (bib2) 2007; 132 Arce Vargas, Furness, Solomon, Joshi, Mekkaoui, Lesko, Miranda Rota, Dahan, Georgiou, Sledzinska (bib21) 2017; 46 Gambardella, Ong, Ruiz, Machiels, de Sanmamed, Tabernero, Spreafico, Renouf, Luen, Galot (bib68) 2023; 83 Furness, Vargas, Peggs, Quezada (bib75) 2014; 35 Plitas, Rudensky (bib5) 2020; 4 Anderson, Joller, Kuchroo (bib19) 2016; 44 Preillon, Cuende, Rabolli, Garnero, Mercier, Wald, Pappalardo, Denies, Jamart, Michaux (bib31) 2021; 20 Sun, Yu, Wang, Yuan, Wang, Hu, Zhang, Pei, Wang, Sun, Yang (bib64) 2023; 13 Baldassari, Rose (bib22) 2017; 14 Harms, Kearns, Iadevaia, Lugovskoy (bib71) 2014; 65 Mazor, Hansen, Yang, Chowdhury, Wang, Stephens, Wu, Dall’Acqua (bib10) 2015; 7 McDonagh, Huhalov, Harms, Adams, Paragas, Oyama, Zhang, Luus, Overland, Nguyen (bib15) 2012; 11 Li, He, Liu, Zheng, Qi, Li, Mao, Liu, Sun, Pan (bib44) 2017; 6 Song, Liu, Dong, Wang, Sha, Liu, Ning, Han, Liu, Zong (bib26) 2021; 11 Ahn, Niu, Kim, Rasco, Mileham, Chung, Vaishampayan, Maurice-Dror, Lo Russo, Golan (bib38) 2020; 31 Gong, Chehrazi-Raffle, Reddi, Salgia (bib48) 2018; 6 Lo, Kim, Tong, Bainbridge, Vernes, Zhang, Lin, Chung, Dennis, Zuchero (bib49) 2017; 292 Fuhrman, Yeh, Seay, Saikumar Lakshmi, Chopra, Zhang, Perry, McClymont, Yadav, Lopez (bib34) 2015; 195 Moreau, Nabholz, Diamantstein, Malek, Shevach, Thèze (bib43) 1987; 17 Kim, Rasmussen, Rudensky (bib51) 2007; 8 Chiesa, Tomasello, Vivier, Vély (bib56) 2005; 42 Kvarnhammar, Veitonmäki, Hägerbrand, Dahlman, Smith, Fritzell, von Schantz, Thagesson, Werchau, Smedenfors (bib63) 2019; 7 Joller, Lozano, Burkett, Patel, Xiao, Zhu, Xia, Tan, Sefik, Yajnik (bib32) 2014; 40 Bray, Laversanne, Sung, Ferlay, Siegel, Soerjomataram, Jemal (bib42) 2024; 74 Du, Li, Liu, Chen, Wei, Luo, Liu, Qi, Wang, Sui (bib12) 2021; 29 Rodriguez-Abreu, Johnson, Hussein, Cobo, Patel, Secen, Lee, Massuti, Hiret, Yang (bib39) 2020 Shimizu, Yamazaki, Sakaguchi (bib66) 1999; 163 Tanaka, Sakaguchi (bib60) 2019; 49 Pandiyan, Zheng, Ishihara, Reed, Lenardo (bib17) 2007; 8 Zhai, Dai, Huang, Chen, Peng, Zhou, Chen, Zhang, Wang, Wang (bib80) 2023; 83 van Gulijk, van Krimpen, Schetters, Eterman, van Elsas, Mankor, Klaase, de Bruijn, van Nimwegen, van Tienhoven (bib82) 2023; 8 Bertrand, Kostine, Barnetche, Truchetet, Schaeverbeke (bib9) 2015; 13 Fourcade, Sun, Chauvin, Ka, Davar, Pagliano, Wang, Saada, Menna, Amin (bib33) 2018; 3 Kurtulus (10.1016/j.ymthe.2024.09.010_bib35) 2015; 125 Zheng (10.1016/j.ymthe.2024.09.010_bib41) 2021; 374 Baldassari (10.1016/j.ymthe.2024.09.010_bib22) 2017; 14 Ahn (10.1016/j.ymthe.2024.09.010_bib38) 2020; 31 Wing (10.1016/j.ymthe.2024.09.010_bib18) 2008; 322 Colombo (10.1016/j.ymthe.2024.09.010_bib73) 2007; 7 Sakaguchi (10.1016/j.ymthe.2024.09.010_bib1) 2020; 38 Pang (10.1016/j.ymthe.2024.09.010_bib65) 2023; 15 Oosterhoff (10.1016/j.ymthe.2024.09.010_bib57) 2022; 43 Anderson (10.1016/j.ymthe.2024.09.010_bib19) 2016; 44 Schaefer (10.1016/j.ymthe.2024.09.010_bib46) 2011; 108 Dovedi (10.1016/j.ymthe.2024.09.010_bib61) 2021; 11 Mazor (10.1016/j.ymthe.2024.09.010_bib16) 2017; 7 Cohen Saban (10.1016/j.ymthe.2024.09.010_bib76) 2023; 8 Rodriguez-Abreu (10.1016/j.ymthe.2024.09.010_bib39) 2020 Levin (10.1016/j.ymthe.2024.09.010_bib27) 2011; 41 Pandiyan (10.1016/j.ymthe.2024.09.010_bib17) 2007; 8 Ridgway (10.1016/j.ymthe.2024.09.010_bib45) 1996; 9 Berezhnoy (10.1016/j.ymthe.2024.09.010_bib62) 2020; 1 Joller (10.1016/j.ymthe.2024.09.010_bib32) 2014; 40 Setiady (10.1016/j.ymthe.2024.09.010_bib79) 2010; 40 Stanietsky (10.1016/j.ymthe.2024.09.010_bib29) 2009; 106 Pereira (10.1016/j.ymthe.2024.09.010_bib58) 2018; 10 Couper (10.1016/j.ymthe.2024.09.010_bib8) 2009; 182 Yamane-Ohnuki (10.1016/j.ymthe.2024.09.010_bib59) 2004; 87 Ge (10.1016/j.ymthe.2024.09.010_bib53) 2021; 12 Rousseau (10.1016/j.ymthe.2024.09.010_bib69) 2023; 8 Fu (10.1016/j.ymthe.2024.09.010_bib2) 2007; 132 Wang (10.1016/j.ymthe.2024.09.010_bib54) 2015; 6 Kim (10.1016/j.ymthe.2024.09.010_bib51) 2007; 8 Solomon (10.1016/j.ymthe.2024.09.010_bib24) 2020; 1 Du (10.1016/j.ymthe.2024.09.010_bib12) 2021; 29 Lo (10.1016/j.ymthe.2024.09.010_bib49) 2017; 292 Chiesa (10.1016/j.ymthe.2024.09.010_bib56) 2005; 42 Berezhnoy (10.1016/j.ymthe.2024.09.010_bib14) 2020; 80 McDonagh (10.1016/j.ymthe.2024.09.010_bib15) 2012; 11 Fuhrman (10.1016/j.ymthe.2024.09.010_bib34) 2015; 195 Sakaguchi (10.1016/j.ymthe.2024.09.010_bib50) 1995; 155 Boyman (10.1016/j.ymthe.2024.09.010_bib47) 2012; 12 Song (10.1016/j.ymthe.2024.09.010_bib26) 2021; 11 Sun (10.1016/j.ymthe.2024.09.010_bib64) 2023; 13 Houacine (10.1016/j.ymthe.2024.09.010_bib25) 2021; 9 Yu (10.1016/j.ymthe.2024.09.010_bib78) 2020; 13 Preillon (10.1016/j.ymthe.2024.09.010_bib31) 2021; 20 Bertrand (10.1016/j.ymthe.2024.09.010_bib9) 2015; 13 Gambardella (10.1016/j.ymthe.2024.09.010_bib68) 2023; 83 Tanaka (10.1016/j.ymthe.2024.09.010_bib60) 2019; 49 Dougall (10.1016/j.ymthe.2024.09.010_bib30) 2017; 276 Onizuka (10.1016/j.ymthe.2024.09.010_bib67) 1999; 59 Plitas (10.1016/j.ymthe.2024.09.010_bib5) 2020; 4 Joller (10.1016/j.ymthe.2024.09.010_bib28) 2011; 186 Kvarnhammar (10.1016/j.ymthe.2024.09.010_bib63) 2019; 7 Moreau (10.1016/j.ymthe.2024.09.010_bib43) 1987; 17 Shimizu (10.1016/j.ymthe.2024.09.010_bib66) 1999; 163 Bray (10.1016/j.ymthe.2024.09.010_bib42) 2024; 74 Gong (10.1016/j.ymthe.2024.09.010_bib48) 2018; 6 Ha (10.1016/j.ymthe.2024.09.010_bib6) 2019; 116 van Gulijk (10.1016/j.ymthe.2024.09.010_bib82) 2023; 8 Huang (10.1016/j.ymthe.2024.09.010_bib74) 2020; 129 Sharma (10.1016/j.ymthe.2024.09.010_bib7) 2019; 25 Han (10.1016/j.ymthe.2024.09.010_bib36) 2020; 11 Piccione (10.1016/j.ymthe.2024.09.010_bib11) 2015; 7 Erfani (10.1016/j.ymthe.2024.09.010_bib4) 2012; 77 Kapic (10.1016/j.ymthe.2024.09.010_bib23) 2004; 58 Harms (10.1016/j.ymthe.2024.09.010_bib71) 2014; 65 Mazor (10.1016/j.ymthe.2024.09.010_bib10) 2015; 7 Finn (10.1016/j.ymthe.2024.09.010_bib40) 2023 Yang (10.1016/j.ymthe.2024.09.010_bib37) 2020; 205 Arce Vargas (10.1016/j.ymthe.2024.09.010_bib21) 2017; 46 Furness (10.1016/j.ymthe.2024.09.010_bib75) 2014; 35 Zhai (10.1016/j.ymthe.2024.09.010_bib80) 2023; 83 Ritter (10.1016/j.ymthe.2024.09.010_bib13) 2022; 10 Fourcade (10.1016/j.ymthe.2024.09.010_bib33) 2018; 3 Du (10.1016/j.ymthe.2024.09.010_bib81) 2023; 11 Li (10.1016/j.ymthe.2024.09.010_bib44) 2017; 6 Zheng (10.1016/j.ymthe.2024.09.010_bib72) 2016; 8 Simpson (10.1016/j.ymthe.2024.09.010_bib77) 2013; 210 Liu (10.1016/j.ymthe.2024.09.010_bib52) 2022; 20 Weiskopf (10.1016/j.ymthe.2024.09.010_bib55) 2015 Frentzas (10.1016/j.ymthe.2024.09.010_bib70) 2021; 39 Zhou (10.1016/j.ymthe.2024.09.010_bib3) 2009; 125 Rogers (10.1016/j.ymthe.2024.09.010_bib20) 1997; 158 |
| References_xml | – volume: 10 start-page: A521 year: 2022 ident: bib13 article-title: 500 INV322, a TME selective CD25 x CTLA4 bispecific antibody approach for depletion of tumor restricted Tregs publication-title: J. Immunother Cancer contributor: fullname: Aversa – volume: 9 start-page: A898 year: 2021 ident: bib25 article-title: 857 Selective Treg depletion in solid tumors with ALD2510, a novel humanized CD25-specific, IL-2 sparing monoclonal antibody publication-title: J. ImmunoTherapy Cancer contributor: fullname: Olive – volume: 11 year: 2020 ident: bib36 article-title: Effective Anti-tumor Response by TIGIT Blockade Associated With FcgammaR Engagement and Myeloid Cell Activation publication-title: Front. Immunol. contributor: fullname: LaFace – volume: 155 start-page: 1151 year: 1995 end-page: 1164 ident: bib50 article-title: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases publication-title: J. Immunol. contributor: fullname: Toda – volume: 8 year: 2023 ident: bib76 article-title: Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy publication-title: Sci. Immunol. contributor: fullname: Dahan – volume: 80 start-page: 2288 year: 2020 ident: bib14 article-title: Investigational CD25 x CTLA-4 bispecific DART® molecule for depletion of tumor infiltrating Tregs via an enhanced Fc-dependent effector mechanism publication-title: Cancer Res. contributor: fullname: Moore – volume: 8 start-page: 551 year: 2016 end-page: 561 ident: bib72 article-title: Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody publication-title: mAbs contributor: fullname: Wang – volume: 11 start-page: A553 year: 2023 ident: bib81 article-title: 491 Generation of an innovative bispecific antibody targeting CCR8/CTLA4 publication-title: J. Immunother Cancer contributor: fullname: Han – volume: 41 start-page: 902 year: 2011 end-page: 915 ident: bib27 article-title: Vstm3 is a member of the CD28 family and an important modulator of T-cell function publication-title: Eur. J. Immunol. contributor: fullname: Ardourel – volume: 163 start-page: 5211 year: 1999 end-page: 5218 ident: bib66 article-title: Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity publication-title: J. Immunol. contributor: fullname: Sakaguchi – volume: 129 year: 2020 ident: bib74 article-title: Multispecific, Multivalent Antibody-Based Molecules Engineered on the DART® and TRIDENTTM Platforms publication-title: Curr. Protoc. Immunol. contributor: fullname: Diedrich – volume: 132 start-page: 2328 year: 2007 end-page: 2339 ident: bib2 article-title: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients publication-title: Gastroenterology contributor: fullname: Zhou – volume: 6 year: 2017 ident: bib44 article-title: A potent human neutralizing antibody Fc-dependently reduces established HBV infections publication-title: Elife contributor: fullname: Pan – volume: 42 start-page: 477 year: 2005 end-page: 484 ident: bib56 article-title: Coordination of activating and inhibitory signals in natural killer cells publication-title: Mol. Immunol. contributor: fullname: Vély – volume: 322 start-page: 271 year: 2008 end-page: 275 ident: bib18 article-title: CTLA-4 control over Foxp3+ regulatory T cell function publication-title: Science contributor: fullname: Sakaguchi – volume: 116 start-page: 609 year: 2019 end-page: 618 ident: bib6 article-title: Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody publication-title: Proc. Natl. Acad. Sci. USA contributor: fullname: Newell – volume: 195 start-page: 145 year: 2015 end-page: 155 ident: bib34 article-title: Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226 publication-title: J. Immunol. contributor: fullname: Lopez – volume: 25 start-page: 1233 year: 2019 end-page: 1238 ident: bib7 article-title: Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers publication-title: Clin. Cancer Res. contributor: fullname: Sharma – year: 2020 ident: bib39 article-title: Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with publication-title: PD-L1-selected NSCLC (CITYSCAPE) contributor: fullname: Yang – volume: 46 start-page: 577 year: 2017 end-page: 586 ident: bib21 article-title: Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors publication-title: Immunity contributor: fullname: Sledzinska – volume: 276 start-page: 112 year: 2017 end-page: 120 ident: bib30 article-title: TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy publication-title: Immunol. Rev. contributor: fullname: Anderson – volume: 43 start-page: 800 year: 2022 end-page: 814 ident: bib57 article-title: Afucosylated IgG responses in humans–structural clues to the regulation of humoral immunity publication-title: Trends Immunol. contributor: fullname: Vidarsson – volume: 292 start-page: 3900 year: 2017 end-page: 3908 ident: bib49 article-title: Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice publication-title: J. Biol. Chem. contributor: fullname: Zuchero – volume: 158 start-page: 649 year: 1997 end-page: 657 ident: bib20 article-title: Visualization of antigen-specific T cell activation and cytokine expression in vivo publication-title: J. Immunol. contributor: fullname: Bucy – volume: 38 start-page: 541 year: 2020 end-page: 566 ident: bib1 article-title: Regulatory T Cells and Human Disease publication-title: Annu. Rev. Immunol. contributor: fullname: Ohkura – volume: 40 start-page: 780 year: 2010 end-page: 786 ident: bib79 article-title: In vivo depletion of CD4+ FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcγRIII+ phagocytes publication-title: Eur. J. Immunol. contributor: fullname: Park – volume: 8 year: 2023 ident: bib69 article-title: Anti-TIGIT therapies for solid tumors: a systematic review publication-title: ESMO Open contributor: fullname: Barlesi – volume: 7 start-page: 880 year: 2007 end-page: 887 ident: bib73 article-title: Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy publication-title: Nat. Rev. Cancer contributor: fullname: Piconese – volume: 35 start-page: 290 year: 2014 end-page: 298 ident: bib75 article-title: Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies publication-title: Trends Immunol. contributor: fullname: Quezada – volume: 8 start-page: 1353 year: 2007 end-page: 1362 ident: bib17 article-title: CD4+ CD25+ Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells publication-title: Nat. Immunol. contributor: fullname: Lenardo – volume: 210 start-page: 1695 year: 2013 end-page: 1710 ident: bib77 article-title: Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma publication-title: J. Exp. Med. contributor: fullname: Wolchok – volume: 7 start-page: 1 year: 2019 end-page: 14 ident: bib63 article-title: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation publication-title: J. Immunother. Cancer contributor: fullname: Smedenfors – volume: 12 start-page: 443 year: 2021 end-page: 464 ident: bib53 article-title: TIGIT and PD1 co-blockade restores ex vivo functions of human tumor-infiltrating CD8+ T cells in hepatocellular carcinoma publication-title: Cell. Mol. Gastroenterol. Hepatol. contributor: fullname: Pan – volume: 40 start-page: 569 year: 2014 end-page: 581 ident: bib32 article-title: Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses publication-title: Immunity contributor: fullname: Yajnik – volume: 1 year: 2020 ident: bib62 article-title: Development and preliminary clinical activity of PD-1-guided CTLA-4 blocking bispecific DART molecule publication-title: Cell Rep. Med. contributor: fullname: Bendell – volume: 8 year: 2023 ident: bib82 article-title: PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance publication-title: Sci. Immunol. contributor: fullname: van Tienhoven – volume: 6 start-page: 368 year: 2015 ident: bib54 article-title: NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy publication-title: Front. Immunol. contributor: fullname: Sondel – volume: 59 start-page: 3128 year: 1999 end-page: 3133 ident: bib67 article-title: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody publication-title: Cancer Res. contributor: fullname: Nakayama – volume: 11 start-page: 1100 year: 2021 end-page: 1117 ident: bib61 article-title: Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T CellsModulated CTLA4 Inhibition via Preferential Binding to PD-1 publication-title: Cancer Discov. contributor: fullname: Wang – volume: 20 start-page: 280 year: 2022 end-page: 293 ident: bib52 article-title: Blocking TIGIT/CD155 signalling reverses CD8 publication-title: J. Transl. Med. contributor: fullname: Zhang – volume: 11 year: 2021 ident: bib26 article-title: Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity publication-title: Sci. Rep. contributor: fullname: Zong – year: 2023 ident: bib40 article-title: Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable publication-title: Locally Advanced or Metastatic Hepatocellular Carcinoma (uHCC) contributor: fullname: Rao Edubilli – volume: 125 start-page: 4053 year: 2015 end-page: 4062 ident: bib35 article-title: TIGIT predominantly regulates the immune response via regulatory T cells publication-title: J. Clin. Invest. contributor: fullname: Anderson – volume: 12 start-page: 180 year: 2012 end-page: 190 ident: bib47 article-title: The role of interleukin-2 during homeostasis and activation of the immune system publication-title: Nat. Rev. Immunol. contributor: fullname: Sprent – volume: 7 start-page: 461 year: 2015 end-page: 469 ident: bib10 article-title: Insights into the molecular basis of a bispecific antibody's target selectivity publication-title: MAbs contributor: fullname: Dall’Acqua – volume: 106 start-page: 17858 year: 2009 end-page: 17863 ident: bib29 article-title: The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity publication-title: Proc. Natl. Acad. Sci. USA contributor: fullname: Achdout – volume: 65 start-page: 95 year: 2014 end-page: 104 ident: bib71 article-title: Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies publication-title: Methods contributor: fullname: Lugovskoy – volume: 13 start-page: 45 year: 2020 ident: bib78 article-title: How to select IgG subclasses in developing anti-tumor therapeutic antibodies publication-title: J. Hematol. Oncol. contributor: fullname: Tian – volume: 15 year: 2023 ident: bib65 article-title: Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity publication-title: MAbs contributor: fullname: Li – volume: 83 start-page: CT110 year: 2023 ident: bib68 article-title: Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors publication-title: Cancer Res. contributor: fullname: Galot – volume: 3 year: 2018 ident: bib33 article-title: CD226 opposes TIGIT to disrupt Tregs in melanoma publication-title: JCI Insight contributor: fullname: Amin – volume: 77 start-page: 306 year: 2012 end-page: 311 ident: bib4 article-title: Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC) publication-title: Lung cancer contributor: fullname: Amani – volume: 6 start-page: 8 year: 2018 end-page: 18 ident: bib48 article-title: Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations publication-title: J. Immunother. Cancer contributor: fullname: Salgia – volume: 374 year: 2021 ident: bib41 article-title: Pan-cancer single-cell landscape of tumor-infiltrating T cells publication-title: Science contributor: fullname: Zhang – volume: 74 start-page: 229 year: 2024 end-page: 263 ident: bib42 article-title: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA. Cancer J. Clin. contributor: fullname: Jemal – volume: 17 start-page: 929 year: 1987 end-page: 935 ident: bib43 article-title: Monoclonal antibodies identify three epitope clusters on the mouse p55 subunit of the interleukin 2 receptor: relationship to the interleukin 2-binding site publication-title: Eur. J. Immunol. contributor: fullname: Thèze – year: 2015 ident: bib55 article-title: Macrophages are critical effectors of antibody therapies for cancer publication-title: MAbs contributor: fullname: Weissman – volume: 87 start-page: 614 year: 2004 end-page: 622 ident: bib59 article-title: Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity publication-title: Biotechnol. Bioeng. contributor: fullname: Uchida – volume: 125 start-page: 1640 year: 2009 end-page: 1648 ident: bib3 article-title: Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients publication-title: Int. J. Cancer contributor: fullname: Zheng – volume: 44 start-page: 989 year: 2016 end-page: 1004 ident: bib19 article-title: Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation publication-title: Immunity contributor: fullname: Kuchroo – volume: 14 start-page: 842 year: 2017 end-page: 858 ident: bib22 article-title: Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis publication-title: Neurotherapeutics contributor: fullname: Rose – volume: 20 start-page: 121 year: 2021 end-page: 131 ident: bib31 article-title: Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies publication-title: Mol. Cancer Ther. contributor: fullname: Michaux – volume: 205 start-page: 2156 year: 2020 end-page: 2168 ident: bib37 article-title: A Cross-species reactive TIGIT-blocking antibody Fc dependently confers potent antitumor effects publication-title: J. Immunol. contributor: fullname: Sui – volume: 58 start-page: 373 year: 2004 end-page: 376 ident: bib23 article-title: Basiliximab, mechanism of action and pharmacological properties publication-title: Med. Arh. contributor: fullname: Kusturica – volume: 108 start-page: 11187 year: 2011 end-page: 11192 ident: bib46 publication-title: Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies contributor: fullname: Imhof-Jung – volume: 8 start-page: 191 year: 2007 end-page: 197 ident: bib51 article-title: Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice publication-title: Nat. Immunol. contributor: fullname: Rudensky – volume: 4 start-page: 459 year: 2020 end-page: 477 ident: bib5 article-title: Regulatory T cells in cancer publication-title: Annu. Rev. Cancer Biol. contributor: fullname: Rudensky – volume: 83 start-page: 5674 year: 2023 ident: bib80 article-title: Anti-CCR8-based bispecific antibodies engineered to preferentially eliminate tumor-infiltrating regulatory T cells: leaving effectors unharmed publication-title: Cancer Res. contributor: fullname: Wang – volume: 11 start-page: 582 year: 2012 end-page: 593 ident: bib15 article-title: Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3Bispecific Antibody Inhibitor of ErbB2/ErbB3 Heterodimer publication-title: Mol. Cancer Ther. contributor: fullname: Nguyen – volume: 31 start-page: S887 year: 2020 ident: bib38 article-title: 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC publication-title: Ann. Oncol. contributor: fullname: Golan – volume: 39 start-page: 2583 year: 2021 ident: bib70 article-title: AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors publication-title: J. Clin. Oncol. contributor: fullname: Tan – volume: 29 start-page: 1572 year: 2021 end-page: 1584 ident: bib12 article-title: A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC publication-title: Mol. Ther. contributor: fullname: Sui – volume: 7 year: 2017 ident: bib16 article-title: Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence publication-title: Sci. Rep. contributor: fullname: Dall'Acqua – volume: 186 start-page: 1338 year: 2011 end-page: 1342 ident: bib28 article-title: Cutting edge: TIGIT has T cell-intrinsic inhibitory functions publication-title: J. Immunol. contributor: fullname: Kuchroo – volume: 13 start-page: 211 year: 2015 end-page: 214 ident: bib9 article-title: Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis publication-title: BMC Med. contributor: fullname: Schaeverbeke – volume: 7 start-page: 946 year: 2015 end-page: 956 ident: bib11 article-title: A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells publication-title: MAbs contributor: fullname: Majeti – volume: 182 start-page: 3985 year: 2009 end-page: 3994 ident: bib8 article-title: Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection publication-title: J. Immunol. contributor: fullname: Johnson – volume: 13 start-page: 3583 year: 2023 end-page: 3597 ident: bib64 article-title: Bispecific antibodies in cancer therapy: Target selection and regulatory requirements publication-title: Acta Pharm. Sin. B contributor: fullname: Yang – volume: 1 start-page: 1153 year: 2020 end-page: 1166 ident: bib24 article-title: CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity publication-title: Nat. Cancer contributor: fullname: Marafioti – volume: 9 start-page: 617 year: 1996 end-page: 621 ident: bib45 article-title: ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization publication-title: Protein Eng. contributor: fullname: Carter – volume: 49 start-page: 1140 year: 2019 end-page: 1146 ident: bib60 article-title: Targeting Treg cells in cancer immunotherapy publication-title: Eur. J. Immunol. contributor: fullname: Sakaguchi – volume: 10 start-page: 693 year: 2018 end-page: 711 ident: bib58 article-title: The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity publication-title: MAbs contributor: fullname: Song – volume: 74 start-page: 229 year: 2024 ident: 10.1016/j.ymthe.2024.09.010_bib42 article-title: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA. Cancer J. Clin. doi: 10.3322/caac.21834 contributor: fullname: Bray – volume: 11 start-page: A553 year: 2023 ident: 10.1016/j.ymthe.2024.09.010_bib81 article-title: 491 Generation of an innovative bispecific antibody targeting CCR8/CTLA4 publication-title: J. Immunother Cancer contributor: fullname: Du – volume: 1 start-page: 1153 year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib24 article-title: CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity publication-title: Nat. Cancer doi: 10.1038/s43018-020-00133-0 contributor: fullname: Solomon – volume: 40 start-page: 780 year: 2010 ident: 10.1016/j.ymthe.2024.09.010_bib79 article-title: In vivo depletion of CD4+ FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcγRIII+ phagocytes publication-title: Eur. J. Immunol. doi: 10.1002/eji.200939613 contributor: fullname: Setiady – volume: 182 start-page: 3985 year: 2009 ident: 10.1016/j.ymthe.2024.09.010_bib8 article-title: Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection publication-title: J. Immunol. doi: 10.4049/jimmunol.0803053 contributor: fullname: Couper – volume: 11 start-page: 1100 year: 2021 ident: 10.1016/j.ymthe.2024.09.010_bib61 article-title: Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T CellsModulated CTLA4 Inhibition via Preferential Binding to PD-1 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-20-1445 contributor: fullname: Dovedi – volume: 42 start-page: 477 year: 2005 ident: 10.1016/j.ymthe.2024.09.010_bib56 article-title: Coordination of activating and inhibitory signals in natural killer cells publication-title: Mol. Immunol. doi: 10.1016/j.molimm.2004.07.030 contributor: fullname: Chiesa – volume: 44 start-page: 989 year: 2016 ident: 10.1016/j.ymthe.2024.09.010_bib19 article-title: Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation publication-title: Immunity doi: 10.1016/j.immuni.2016.05.001 contributor: fullname: Anderson – volume: 8 start-page: 551 year: 2016 ident: 10.1016/j.ymthe.2024.09.010_bib72 article-title: Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody publication-title: mAbs doi: 10.1080/19420862.2015.1136762 contributor: fullname: Zheng – volume: 29 start-page: 1572 year: 2021 ident: 10.1016/j.ymthe.2024.09.010_bib12 article-title: A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC publication-title: Mol. Ther. doi: 10.1016/j.ymthe.2021.01.006 contributor: fullname: Du – volume: 155 start-page: 1151 year: 1995 ident: 10.1016/j.ymthe.2024.09.010_bib50 article-title: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases publication-title: J. Immunol. doi: 10.4049/jimmunol.155.3.1151 contributor: fullname: Sakaguchi – volume: 25 start-page: 1233 year: 2019 ident: 10.1016/j.ymthe.2024.09.010_bib7 article-title: Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-0762 contributor: fullname: Sharma – volume: 10 start-page: 693 year: 2018 ident: 10.1016/j.ymthe.2024.09.010_bib58 article-title: The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity publication-title: MAbs doi: 10.1080/19420862.2018.1466767 contributor: fullname: Pereira – volume: 15 year: 2023 ident: 10.1016/j.ymthe.2024.09.010_bib65 article-title: Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity publication-title: MAbs doi: 10.1080/19420862.2023.2180794 contributor: fullname: Pang – volume: 49 start-page: 1140 year: 2019 ident: 10.1016/j.ymthe.2024.09.010_bib60 article-title: Targeting Treg cells in cancer immunotherapy publication-title: Eur. J. Immunol. doi: 10.1002/eji.201847659 contributor: fullname: Tanaka – volume: 20 start-page: 121 year: 2021 ident: 10.1016/j.ymthe.2024.09.010_bib31 article-title: Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-20-0464 contributor: fullname: Preillon – volume: 108 start-page: 11187 year: 2011 ident: 10.1016/j.ymthe.2024.09.010_bib46 contributor: fullname: Schaefer – volume: 163 start-page: 5211 year: 1999 ident: 10.1016/j.ymthe.2024.09.010_bib66 article-title: Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity publication-title: J. Immunol. doi: 10.4049/jimmunol.163.10.5211 contributor: fullname: Shimizu – volume: 125 start-page: 1640 year: 2009 ident: 10.1016/j.ymthe.2024.09.010_bib3 article-title: Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients publication-title: Int. J. Cancer doi: 10.1002/ijc.24556 contributor: fullname: Zhou – volume: 129 year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib74 article-title: Multispecific, Multivalent Antibody-Based Molecules Engineered on the DART® and TRIDENTTM Platforms publication-title: Curr. Protoc. Immunol. doi: 10.1002/cpim.95 contributor: fullname: Huang – volume: 6 start-page: 8 year: 2018 ident: 10.1016/j.ymthe.2024.09.010_bib48 article-title: Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0316-z contributor: fullname: Gong – volume: 7 start-page: 880 year: 2007 ident: 10.1016/j.ymthe.2024.09.010_bib73 article-title: Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy publication-title: Nat. Rev. Cancer doi: 10.1038/nrc2250 contributor: fullname: Colombo – volume: 186 start-page: 1338 year: 2011 ident: 10.1016/j.ymthe.2024.09.010_bib28 article-title: Cutting edge: TIGIT has T cell-intrinsic inhibitory functions publication-title: J. Immunol. doi: 10.4049/jimmunol.1003081 contributor: fullname: Joller – volume: 12 start-page: 180 year: 2012 ident: 10.1016/j.ymthe.2024.09.010_bib47 article-title: The role of interleukin-2 during homeostasis and activation of the immune system publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3156 contributor: fullname: Boyman – volume: 20 start-page: 280 year: 2022 ident: 10.1016/j.ymthe.2024.09.010_bib52 article-title: Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer publication-title: J. Transl. Med. doi: 10.1186/s12967-022-03480-x contributor: fullname: Liu – volume: 292 start-page: 3900 year: 2017 ident: 10.1016/j.ymthe.2024.09.010_bib49 article-title: Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice publication-title: J. Biol. Chem. doi: 10.1074/jbc.M116.767749 contributor: fullname: Lo – volume: 205 start-page: 2156 year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib37 article-title: A Cross-species reactive TIGIT-blocking antibody Fc dependently confers potent antitumor effects publication-title: J. Immunol. doi: 10.4049/jimmunol.1901413 contributor: fullname: Yang – volume: 8 year: 2023 ident: 10.1016/j.ymthe.2024.09.010_bib76 article-title: Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.add8005 contributor: fullname: Cohen Saban – volume: 8 year: 2023 ident: 10.1016/j.ymthe.2024.09.010_bib82 article-title: PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abn6173 contributor: fullname: van Gulijk – volume: 87 start-page: 614 year: 2004 ident: 10.1016/j.ymthe.2024.09.010_bib59 article-title: Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity publication-title: Biotechnol. Bioeng. doi: 10.1002/bit.20151 contributor: fullname: Yamane-Ohnuki – volume: 322 start-page: 271 year: 2008 ident: 10.1016/j.ymthe.2024.09.010_bib18 article-title: CTLA-4 control over Foxp3+ regulatory T cell function publication-title: Science doi: 10.1126/science.1160062 contributor: fullname: Wing – year: 2015 ident: 10.1016/j.ymthe.2024.09.010_bib55 article-title: Macrophages are critical effectors of antibody therapies for cancer contributor: fullname: Weiskopf – volume: 11 year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib36 article-title: Effective Anti-tumor Response by TIGIT Blockade Associated With FcgammaR Engagement and Myeloid Cell Activation publication-title: Front. Immunol. contributor: fullname: Han – volume: 10 start-page: A521 year: 2022 ident: 10.1016/j.ymthe.2024.09.010_bib13 article-title: 500 INV322, a TME selective CD25 x CTLA4 bispecific antibody approach for depletion of tumor restricted Tregs publication-title: J. Immunother Cancer contributor: fullname: Ritter – volume: 58 start-page: 373 year: 2004 ident: 10.1016/j.ymthe.2024.09.010_bib23 article-title: Basiliximab, mechanism of action and pharmacological properties publication-title: Med. Arh. contributor: fullname: Kapic – volume: 8 start-page: 191 year: 2007 ident: 10.1016/j.ymthe.2024.09.010_bib51 article-title: Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice publication-title: Nat. Immunol. doi: 10.1038/ni1428 contributor: fullname: Kim – volume: 132 start-page: 2328 year: 2007 ident: 10.1016/j.ymthe.2024.09.010_bib2 article-title: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.03.102 contributor: fullname: Fu – year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib39 article-title: Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with contributor: fullname: Rodriguez-Abreu – volume: 3 year: 2018 ident: 10.1016/j.ymthe.2024.09.010_bib33 article-title: CD226 opposes TIGIT to disrupt Tregs in melanoma publication-title: JCI Insight doi: 10.1172/jci.insight.121157 contributor: fullname: Fourcade – volume: 59 start-page: 3128 year: 1999 ident: 10.1016/j.ymthe.2024.09.010_bib67 article-title: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody publication-title: Cancer Res. contributor: fullname: Onizuka – volume: 116 start-page: 609 year: 2019 ident: 10.1016/j.ymthe.2024.09.010_bib6 article-title: Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1812186116 contributor: fullname: Ha – volume: 276 start-page: 112 year: 2017 ident: 10.1016/j.ymthe.2024.09.010_bib30 article-title: TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy publication-title: Immunol. Rev. doi: 10.1111/imr.12518 contributor: fullname: Dougall – volume: 35 start-page: 290 year: 2014 ident: 10.1016/j.ymthe.2024.09.010_bib75 article-title: Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies publication-title: Trends Immunol. doi: 10.1016/j.it.2014.05.002 contributor: fullname: Furness – volume: 6 year: 2017 ident: 10.1016/j.ymthe.2024.09.010_bib44 article-title: A potent human neutralizing antibody Fc-dependently reduces established HBV infections publication-title: Elife doi: 10.7554/eLife.26738 contributor: fullname: Li – volume: 11 start-page: 582 year: 2012 ident: 10.1016/j.ymthe.2024.09.010_bib15 article-title: Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3Bispecific Antibody Inhibitor of ErbB2/ErbB3 Heterodimer publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-11-0820 contributor: fullname: McDonagh – volume: 17 start-page: 929 year: 1987 ident: 10.1016/j.ymthe.2024.09.010_bib43 article-title: Monoclonal antibodies identify three epitope clusters on the mouse p55 subunit of the interleukin 2 receptor: relationship to the interleukin 2-binding site publication-title: Eur. J. Immunol. doi: 10.1002/eji.1830170706 contributor: fullname: Moreau – volume: 12 start-page: 443 year: 2021 ident: 10.1016/j.ymthe.2024.09.010_bib53 article-title: TIGIT and PD1 co-blockade restores ex vivo functions of human tumor-infiltrating CD8+ T cells in hepatocellular carcinoma publication-title: Cell. Mol. Gastroenterol. Hepatol. doi: 10.1016/j.jcmgh.2021.03.003 contributor: fullname: Ge – volume: 9 start-page: A898 year: 2021 ident: 10.1016/j.ymthe.2024.09.010_bib25 article-title: 857 Selective Treg depletion in solid tumors with ALD2510, a novel humanized CD25-specific, IL-2 sparing monoclonal antibody publication-title: J. ImmunoTherapy Cancer contributor: fullname: Houacine – volume: 210 start-page: 1695 year: 2013 ident: 10.1016/j.ymthe.2024.09.010_bib77 article-title: Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma publication-title: J. Exp. Med. doi: 10.1084/jem.20130579 contributor: fullname: Simpson – volume: 39 start-page: 2583 year: 2021 ident: 10.1016/j.ymthe.2024.09.010_bib70 article-title: AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2021.39.15_suppl.2583 contributor: fullname: Frentzas – volume: 13 start-page: 3583 year: 2023 ident: 10.1016/j.ymthe.2024.09.010_bib64 article-title: Bispecific antibodies in cancer therapy: Target selection and regulatory requirements publication-title: Acta Pharm. Sin. B doi: 10.1016/j.apsb.2023.05.023 contributor: fullname: Sun – volume: 40 start-page: 569 year: 2014 ident: 10.1016/j.ymthe.2024.09.010_bib32 article-title: Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses publication-title: Immunity doi: 10.1016/j.immuni.2014.02.012 contributor: fullname: Joller – volume: 43 start-page: 800 year: 2022 ident: 10.1016/j.ymthe.2024.09.010_bib57 article-title: Afucosylated IgG responses in humans–structural clues to the regulation of humoral immunity publication-title: Trends Immunol. doi: 10.1016/j.it.2022.08.001 contributor: fullname: Oosterhoff – volume: 7 year: 2017 ident: 10.1016/j.ymthe.2024.09.010_bib16 article-title: Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence publication-title: Sci. Rep. doi: 10.1038/srep40098 contributor: fullname: Mazor – volume: 80 start-page: 2288 year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib14 article-title: Investigational CD25 x CTLA-4 bispecific DART® molecule for depletion of tumor infiltrating Tregs via an enhanced Fc-dependent effector mechanism publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2020-2288 contributor: fullname: Berezhnoy – volume: 125 start-page: 4053 year: 2015 ident: 10.1016/j.ymthe.2024.09.010_bib35 article-title: TIGIT predominantly regulates the immune response via regulatory T cells publication-title: J. Clin. Invest. doi: 10.1172/JCI81187 contributor: fullname: Kurtulus – volume: 46 start-page: 577 year: 2017 ident: 10.1016/j.ymthe.2024.09.010_bib21 article-title: Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors publication-title: Immunity doi: 10.1016/j.immuni.2017.03.013 contributor: fullname: Arce Vargas – year: 2023 ident: 10.1016/j.ymthe.2024.09.010_bib40 article-title: Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable contributor: fullname: Finn – volume: 65 start-page: 95 year: 2014 ident: 10.1016/j.ymthe.2024.09.010_bib71 article-title: Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies publication-title: Methods doi: 10.1016/j.ymeth.2013.07.017 contributor: fullname: Harms – volume: 195 start-page: 145 year: 2015 ident: 10.1016/j.ymthe.2024.09.010_bib34 article-title: Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226 publication-title: J. Immunol. doi: 10.4049/jimmunol.1402381 contributor: fullname: Fuhrman – volume: 14 start-page: 842 year: 2017 ident: 10.1016/j.ymthe.2024.09.010_bib22 article-title: Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis publication-title: Neurotherapeutics doi: 10.1007/s13311-017-0553-8 contributor: fullname: Baldassari – volume: 13 start-page: 211 year: 2015 ident: 10.1016/j.ymthe.2024.09.010_bib9 article-title: Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis publication-title: BMC Med. doi: 10.1186/s12916-015-0455-8 contributor: fullname: Bertrand – volume: 41 start-page: 902 year: 2011 ident: 10.1016/j.ymthe.2024.09.010_bib27 article-title: Vstm3 is a member of the CD28 family and an important modulator of T-cell function publication-title: Eur. J. Immunol. doi: 10.1002/eji.201041136 contributor: fullname: Levin – volume: 31 start-page: S887 year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib38 article-title: 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.08.1714 contributor: fullname: Ahn – volume: 374 year: 2021 ident: 10.1016/j.ymthe.2024.09.010_bib41 article-title: Pan-cancer single-cell landscape of tumor-infiltrating T cells publication-title: Science doi: 10.1126/science.abe6474 contributor: fullname: Zheng – volume: 83 start-page: CT110 year: 2023 ident: 10.1016/j.ymthe.2024.09.010_bib68 article-title: Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2023-CT110 contributor: fullname: Gambardella – volume: 13 start-page: 45 year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib78 article-title: How to select IgG subclasses in developing anti-tumor therapeutic antibodies publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-020-00876-4 contributor: fullname: Yu – volume: 38 start-page: 541 year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib1 article-title: Regulatory T Cells and Human Disease publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev-immunol-042718-041717 contributor: fullname: Sakaguchi – volume: 7 start-page: 946 year: 2015 ident: 10.1016/j.ymthe.2024.09.010_bib11 article-title: A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells publication-title: MAbs doi: 10.1080/19420862.2015.1062192 contributor: fullname: Piccione – volume: 9 start-page: 617 year: 1996 ident: 10.1016/j.ymthe.2024.09.010_bib45 article-title: ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization publication-title: Protein Eng. doi: 10.1093/protein/9.7.617 contributor: fullname: Ridgway – volume: 7 start-page: 1 year: 2019 ident: 10.1016/j.ymthe.2024.09.010_bib63 article-title: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation publication-title: J. Immunother. Cancer contributor: fullname: Kvarnhammar – volume: 83 start-page: 5674 year: 2023 ident: 10.1016/j.ymthe.2024.09.010_bib80 article-title: Anti-CCR8-based bispecific antibodies engineered to preferentially eliminate tumor-infiltrating regulatory T cells: leaving effectors unharmed publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2023-5674 contributor: fullname: Zhai – volume: 4 start-page: 459 year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib5 article-title: Regulatory T cells in cancer publication-title: Annu. Rev. Cancer Biol. doi: 10.1146/annurev-cancerbio-030419-033428 contributor: fullname: Plitas – volume: 77 start-page: 306 year: 2012 ident: 10.1016/j.ymthe.2024.09.010_bib4 article-title: Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC) publication-title: Lung cancer doi: 10.1016/j.lungcan.2012.04.011 contributor: fullname: Erfani – volume: 8 start-page: 1353 year: 2007 ident: 10.1016/j.ymthe.2024.09.010_bib17 article-title: CD4+ CD25+ Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells publication-title: Nat. Immunol. doi: 10.1038/ni1536 contributor: fullname: Pandiyan – volume: 1 year: 2020 ident: 10.1016/j.ymthe.2024.09.010_bib62 article-title: Development and preliminary clinical activity of PD-1-guided CTLA-4 blocking bispecific DART molecule publication-title: Cell Rep. Med. contributor: fullname: Berezhnoy – volume: 7 start-page: 461 year: 2015 ident: 10.1016/j.ymthe.2024.09.010_bib10 article-title: Insights into the molecular basis of a bispecific antibody's target selectivity publication-title: MAbs doi: 10.1080/19420862.2015.1022695 contributor: fullname: Mazor – volume: 158 start-page: 649 year: 1997 ident: 10.1016/j.ymthe.2024.09.010_bib20 article-title: Visualization of antigen-specific T cell activation and cytokine expression in vivo publication-title: J. Immunol. doi: 10.4049/jimmunol.158.2.649 contributor: fullname: Rogers – volume: 6 start-page: 368 year: 2015 ident: 10.1016/j.ymthe.2024.09.010_bib54 article-title: NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy publication-title: Front. Immunol. doi: 10.3389/fimmu.2015.00368 contributor: fullname: Wang – volume: 8 year: 2023 ident: 10.1016/j.ymthe.2024.09.010_bib69 article-title: Anti-TIGIT therapies for solid tumors: a systematic review publication-title: ESMO Open doi: 10.1016/j.esmoop.2023.101184 contributor: fullname: Rousseau – volume: 11 year: 2021 ident: 10.1016/j.ymthe.2024.09.010_bib26 article-title: Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity publication-title: Sci. Rep. doi: 10.1038/s41598-021-02449-y contributor: fullname: Song – volume: 106 start-page: 17858 year: 2009 ident: 10.1016/j.ymthe.2024.09.010_bib29 article-title: The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0903474106 contributor: fullname: Stanietsky |
| SSID | ssj0011596 |
| Score | 2.4881203 |
| Snippet | Intratumoral regulatory T cells (Tregs) express high levels of CD25 and TIGIT, which are also recognized as markers of effector T cell (Teff) activation.... Intratumoral regulatory T cells (Tregs) express high levels of CD25 and TIGIT, which are also recognized as markers of effector T cell (Teff) activation.... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| SubjectTerms | bispecific antibody bsAb CD25 intratumoral regulatory T cells TIGIT Treg depletion |
| Title | A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion |
| URI | https://dx.doi.org/10.1016/j.ymthe.2024.09.010 https://www.ncbi.nlm.nih.gov/pubmed/39245938 https://www.proquest.com/docview/3102069749 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELZCKlAvCMorvGQkbstGG-_71qhQWqpygFRNuVi21wuJ2qRqN4f2j_CD-sc647V3E9Ei6GUVWYl35e-LPTP7zQwh77VMymgA3oksisyHEy_xZZKnPlMii-MyLaQRY-5_TXYOoi_jeNzpbC5nl1Syry5vzCu5C6owBrhilux_INtMCgPwGfCFKyAM13_CeOhtfWQxvuvO09Hu592RJyeYOonyHw-WbCLnBeb1FQvUXeGAXy1OUDapbNMI16bn3LTDQRXRBKO95luYuX-mf3oY20fFLJbptiC6FlCut65XrRYnONRGJDCeNNT78UvMbQzguB09stHqbWEP0KWxIzF1x6qNSrDIyK7SNlTm0mVW1JzYa8lHI_PGvbsOI0z7FyfwzH2c1FSgtarX1aLY33EqnAklsOATxffIGoOtJuuSteHet8O95k0SmGsmw8zd2lWeMhq_P251m3Vym_dhrJDRI_LQug90WHPhMeno2Qa5XzcUvdggD_atVOIJOR1SJMfVb0MM2hKDOmJQSwzaEoM6YlBLDNoQgy4TgyIxKBKDNsR4Sg62P422dnzbXsNX6KeCXwWbdxKEucZ0ZlFkUuey1EJoWSaBTJkQspSDUmUiZ5juA9akKlLNVFAEYcnCZ6Q7m8_0C0JhIyjDDCxDJcBcVEKELBRYWV8MFNb475EPbln5aV1FhTt54ZQbFDiiwIOcAwo9kril59YQrA08Dlz5-w_fOaA4bJO4DGKm54tzDl4MC2ATivIeeV4j2DwJuAhRDNx5edfbviLr7X_gNelWZwv9BmzVSr61dLwGl_iW8Q |
| link.rule.ids | 315,783,787,27938,27939 |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+CD25%C3%97TIGIT+bispecific+antibody+induces+anti-tumor+activity+through+selective+intratumoral+Treg+cell+depletion&rft.jtitle=Molecular+therapy&rft.au=Wei%2C+Xin&rft.au=Zhao%2C+Linlin&rft.au=Yang%2C+Fang&rft.au=Yang%2C+Yajing&rft.date=2024-09-07&rft.pub=Elsevier+Inc&rft.issn=1525-0016&rft_id=info:doi/10.1016%2Fj.ymthe.2024.09.010&rft.externalDocID=S1525001624005975 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1525-0016&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1525-0016&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1525-0016&client=summon |